Home > News > Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting
Supportive Cancer Care
Read Time: < 1 min

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Published Online: March 16th 2018 European Oncology & Haematology, 2018;14(1):[Online only]
Authors: Bernardo L Rapoport, Pere Gascon, Florian Scotte, Karin Jordan, Massimo Di Maio, Sussanne Borjeson, Sam H Ahmedzai
Quick Links:
Article
Article Information
Article:

The authors of the aforementioned article would like to make revisions to the labels in Figure 1 as shown below. The article has been corrected online.

Article Information:

Further Resources

Share this Article
Related Content In Supportive Cancer Care
Supportive Cancer Care
Cancer Nursing Deserves Better Recognition
Daniel Kelly Read Time: < 1 min

European Oncology & Haematology, 2019:15(1):19–20 DOI: https://doi.org/10.17925/EOH.2019.15.1.19

Cancer is a growing problem that demands the best from all sectors of the global health workforce.1 Cancer nurses make up the largest proportion of this workforce and, as well as being responsible for direct care delivery, also aim to address the unmet needs of patients and carers, such as the management of side-effects. Nurses care […]

Supportive Cancer Care
Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting
Bernardo L Rapoport, Pere Gascon, Florian Scotte Read Time: < 1 min

European Oncology & Haematology, 2018;14(1):[Online only]

The authors of the aforementioned article would like to make revisions to the labels in Figure 1 as shown below. The article has been corrected online.

Biosimilars, Supportive Cancer Care
The Impact of Biosimilars in Supportive Care in Cancer
Paul Cornes, Matti S Aapro Read Time: < 1 min

European Oncology & Haematology. 2018;14(1):20–32 DOI: https://doi.org/10.17925/EOH.2018.14.1.20

Biosimilars, which are copies of patent-expired large-molecule biologic drugs (Table 1),1–8 offer the same rationale as generic drugs. They can give patients, hospitals and healthcare systems the opportunity to expand patient access to care and offer potential budget savings to reinvest (Table 2).1,2,9 They are designed to be similar in effectiveness, safety and quality to […]

Trending In Supportive Cancer Care:

Cancer Nursing Deserves Better Recognition
Supportive Cancer Care
    • More Actions
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72